Investigational Drug Information for Marizomib
✉ Email this page to a colleague
What is the drug development status for Marizomib?
Marizomib is an investigational drug.
There have been 12 clinical trials for Marizomib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 26th 2018.
The most common disease conditions in clinical trials are Glioma, Neoplasms, Plasma Cell, and Glioblastoma. The leading clinical trial sponsors are Celgene, Triphase Research and Development I Corporation, and Triphase.
There are four hundred and twenty-three US patents protecting this investigational drug and five international patents.
Summary for Marizomib
| US Patents | 423 |
| International Patents | 5,160 |
| US Patent Applications | 2,172 |
| WIPO Patent Applications | 1,208 |
| Japanese Patent Applications | 417 |
| Clinical Trial Progress | Phase 2 (2018-07-26) |
| Vendors | 33 |
Recent Clinical Trials for Marizomib
| Title | Sponsor | Phase |
|---|---|---|
| Marizomib Central Nervous System (CNS) | Bristol-Myers Squibb | Phase 2 |
| Marizomib Central Nervous System (CNS) | Dana-Farber Cancer Institute | Phase 2 |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG | Celgene | Phase 1 |
Clinical Trial Summary for Marizomib
Top disease conditions for Marizomib
Top clinical trial sponsors for Marizomib
US Patents for Marizomib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Marizomib | ⤷ Try a Trial | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Try a Trial |
| Marizomib | ⤷ Try a Trial | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | ⤷ Try a Trial |
| Marizomib | ⤷ Try a Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| Marizomib | ⤷ Try a Trial | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try a Trial |
| Marizomib | ⤷ Try a Trial | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (San Diego, CA) | ⤷ Try a Trial |
| Marizomib | ⤷ Try a Trial | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Try a Trial |
| Marizomib | ⤷ Try a Trial | Anti-tigit antibodies and methods of use | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Marizomib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Marizomib | Australia | AU2015244171 | 2034-04-11 | ⤷ Try a Trial |
| Marizomib | Australia | AU2015244179 | 2034-04-11 | ⤷ Try a Trial |
| Marizomib | Canada | CA2945128 | 2034-04-11 | ⤷ Try a Trial |
| Marizomib | Canada | CA2945129 | 2034-04-11 | ⤷ Try a Trial |
| Marizomib | China | CN106414451 | 2034-04-11 | ⤷ Try a Trial |
| Marizomib | China | CN106459063 | 2034-04-11 | ⤷ Try a Trial |
| Marizomib | European Patent Office | EP3129377 | 2034-04-11 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
